Guérin B

ORCID: 0000-0002-0319-4512 · 1 paper in corpus

2026

A phase I study to evaluate the dosimetry and safety of [89Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis.

European journal of nuclear medicine and molecular imaging ·doi:10.1007/s00259-026-07853-y

PURPOSE: Misfolded superoxide dismutase-1 (mSOD1) is an abnormal protein observed in amyotrophic lateral sclerosis (ALS) and constitutes a therapeutic target. The present study evaluated the biodistribution, dosimetry, and safety of a new a…